The Maharashtra Food and Drug Administration (FDA) has initiated a significant inquiry into a promotional campaign featuring prominent Bollywood actors Shah Rukh Khan, Ajay Devgn, and Tiger Shroff. This move follows their appearances in advertisements for a popular pan masala brand, specifically a product marketed as a cardamom-based mouth freshener. The regulatory body is scrutinizing whether this campaign inadvertently functions as a form of surrogate advertising, a practice designed to promote products with advertising restrictions by associating them with seemingly innocuous alternatives.
The central point of contention, as detailed in a nine-page show-cause notice, revolves around the branding strategy employed in the Vimal Elaichi campaign. The FDA asserts that the product’s name and overall presentation could forge a strong association with the brand’s well-known pan masala offerings. This, the FDA suggests, has the potential to mislead consumers, effectively promoting a legal mouth freshener while simultaneously bolstering brand recognition for a product category (pan masala) that faces stringent advertising limitations. The actors involved have reportedly been instructed to cease their participation in the campaign and remove any associated promotional content from their social media platforms, with an opportunity provided for them to present their justifications.
The FDA’s concern is not with the consumption of cardamom itself, but rather with the strategic use of branding. Regulators are keen to ascertain whether the consistent use of the “Vimal” identity serves a purpose beyond merely advertising the legal mouth freshener. They are specifically investigating if this branding is intended to “maintain, reinforce or enhance” an existing identity already linked to pan masala or other tobacco-related products. This scrutiny falls under the umbrella of preventing surrogate advertising, which is a key focus given the restrictions on advertising cigarettes and other tobacco products under Section 5 of the Cigarettes and Other Tobacco Products Act, 2003.
The scope of this inquiry extends directly to the celebrities who lent their star power to the campaign. Shah Rukh Khan, Ajay Devgn, and Tiger Shroff have been asked to furnish explanations regarding their involvement. The FDA has also referenced the Central Consumer Protection Authority’s Guidelines for Prevention of Misleading Advertisements and Endorsements for Misleading Advertisements, 2022, underscoring the legal framework guiding their actions. As part of this comprehensive investigation, the actors are expected to provide a range of details, including their endorsement agreements, comprehensive campaign information, payment structures, and a clear outline of the due diligence they undertook before associating themselves with the advertisement. It’s crucial to understand that these notices are not a final verdict of wrongdoing, but rather a formal request for clarification and a chance for the recipients to defend their positions.
The potential ramifications of this investigation could be significant. The notices reportedly refer to provisions concerning misleading advertisements and celebrity endorsements, hinting at possible financial penalties ranging from Rs 10 lakh to Rs 50 lakh, and even potential restrictions on endorsing products for up to three years. Any final action, however, will be contingent upon the FDA’s thorough assessment of the actors’ responses and the applicable legal provisions. This development unfolds against the backdrop of Maharashtra’s sustained efforts to regulate gutka and pan masala products, particularly those containing prohibited ingredients. The state has a history of legal challenges and regulatory actions in this domain, with the Bombay High Court previously upholding the implementation of orders by the Maharashtra Food Safety Commissioner under the Food Safety and Standards Act, 2006.
Upon receiving the actors’ responses, the Maharashtra FDA will carefully review the explanations and any supplementary material provided. This will determine whether further proceedings are deemed necessary. This ongoing controversy has once again ignited public discussion about celebrity endorsements and the ethical implications of advertising practices, particularly when a seemingly legitimate product carries branding that is intrinsically linked to a product category facing stringent advertising limitations.
